Scarica l'app Stockscreener
0.388
2.46%
0.0093
Elevation Oncology Inc Borsa (ELEV) Ultime notizie
Analyzing Ratios: Elevation Oncology Inc (ELEV)’s Financial Story Unveiled - DWinneX
Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
Research Analysts Set Expectations for ELEV FY2025 Earnings - Defense World
Q2 Earnings Estimate for ELEV Issued By Leerink Partnrs - Defense World
Equities Analysts Issue Forecasts for ELEV Q3 Earnings - Defense World
Wedbush Forecasts Reduced Earnings for Elevation Oncology - Defense World
Elevation Oncology (NASDAQ:ELEV) Cut to “Hold” at TD Cowen - Defense World
HC Wainwright Downgrades Elevation Oncology (NASDAQ:ELEV) to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Stock Rating Lowered by HC Wainwright - Defense World
Elevation Oncology (NASDAQ:ELEV) Downgraded by HC Wainwright to Neutral - Defense World
Elevation Oncology (NASDAQ:ELEV) Receives Market Perform Rating from JMP Securities - Defense World
Elevation Oncology (NASDAQ:ELEV) Lowered to Hold Rating by William Blair - Defense World
Elevation Oncology’s (ELEV) Neutral Rating Reaffirmed at HC Wainwright - Defense World
ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc.ELEV - Business Wire
Elevation Oncology (ELEV) Receives Analyst Rating Update | ELEV Stock News - GuruFocus
This McDonald's Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Elevation Oncology (ELEV) Receives Downgrade from HC Wainwright & Co. | ELEV Stock News - GuruFocus
TD Cowen Downgrades Elevation Oncology to Hold From Buy - MarketScreener
HC Wainwright Downgrades Elevation Oncology to Neutral From Buy - marketscreener.com
Elevation Oncology (ELEV) Downgraded by H.C. Wainwright Amid Mer - GuruFocus
Elevation Oncology agrees to be acquired by Concentra - The Pharma Letter
Jane Street Group LLC Acquires 41,215 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Millennium Management LLC Boosts Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology agrees to Concentra Biosciences buyout By Investing.com - Investing.com South Africa
Elevation Oncology (ELEV) Downgraded Following Acquisition News - GuruFocus
Elevation Oncology (ELEV) Downgraded by William Blair Following Acquisition Announcement | ELEV Stock News - GuruFocus
Elevation Oncology (ELEV) to be Acquired by Concentra Biosciences | ELEV Stock News - GuruFocus
Concentra to acquire Elevation in bid to eliminate another biotech ‘zombie’ - BioPharma Dive
Elevation Oncology Accepts a Buyout Offer from Concentra Biosciences - marketscreener.com
Concentra Biosciences, LLC entered into a definitive merger agreement to acquire Elevation Oncology, Inc. for $21.4 million. - marketscreener.com
ELEV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Elevation Oncology, Inc. Is Fair to Shareholders - Business Wire
Elevation Oncology stock soars on Concentra merger agreement By Investing.com - Investing.com South Africa
Elevation Oncology stock soars on Concentra merger agreement - Investing.com Australia
Concentra buys out another struggling Boston biotech - The Business Journals
Elevation Oncology agrees to Concentra Biosciences buyout - Investing.com
Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR - marketscreener.com
Elevation Oncology Merges with Concentra Biosciences - TipRanks
Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right - PR Newswire
Deutsche Bank AG Has $106,000 Stock Holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Northern Trust Corp Purchases 59,392 Shares of Elevation Oncology, Inc. (NASDAQ:ELEV) - Defense World
Elevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of “Hold” from Analysts - Defense World
Elevation Oncology Reports Q1 2025 Financial Results - TipRanks
William Blair Remains a Buy on Elevation Oncology (ELEV) - The Globe and Mail
Elevation Oncology Explores Strategic Alternatives - marketscreener.com
Elevation Oncology Advances Novel HER3 ADC Program While Securing Cash Runway Through 2026 - Stock Titan
Elevation Oncology, Inc. SEC 10-Q Report - TradingView
Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Allogene's Q1 Earnings In Line With Estimates, Sales Nil - Barchart.com
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):